Former Speaker of the US House of Representatives Newt Gingrich has joined Pathway Genomics' strategic advisory board. As a legislator, Gingrich was involved in efforts to increase the National Institutes of Health's budget and to reform Medicare. He also put forth proposals to improve the US Food and Drug Administration's activities. He left Congress in 1999 and founded the Center for Health Transformation in 2003. He ran unsuccessfully for president in 2012.
Robert Wayman retired from Affymetrix's board on Feb. 20, the company said in a regulatory document. He had served on the board since 2007, the company said, and was last reelected in June 2014. Wayman was a former executive vice president and CFO at Hewlett-Packard.
Genetic Technologies appointed Eutillio Buccilli its CEO. Buccilli joined the company in June 2014 as CFO and later also took on the role of Genetic Technologies' COO. He has more than 35 years of senior management experience in the financial services, contracting and recruitment, property, and retail industries, including at General Electric, Computer Science, and Coles Myer. Genetic Technologies' former CEO Alison Mew resigned in December.
UK molecular diagnostics firm Biofortuna has named Ian Johnson its new chairman, replacing Mark Hurley, who will remain on the board as a non-executive director. Johnson was founder and CEO of Biotrace International. He also is currently non-executive chairman of Celsis Group and Cyprotex, and is an operational advisor for Harwood Private Equity, an investor in Celsis and Cyprotex.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.